Following a number of recent transactions in the space, PMSI share insights on the RWD/RWE landscape.
Our key insights:
- In the last few years, Digital Health solutions have seen rapid adoption driven in part by greater value placed on healthcare post-COVID – as governments and corporations aim to generate more value from the data inherent within healthcare systems worldwide
- Real World Data (RWD) and Evidence (RWE) solutions in particular have seen strong interest due to growing regulatory support and patient data availability, as well as a shift towards performance-based contracts alongside Pharma investment into advanced data analytics
- As a result, what has traditionally been a space for venture capital is increasingly attracting private equity and other later-stage investors as they seek to own datasets underlying the shift towards a more digital healthcare system
Read the full article below:
Article
PMSI supports Foresight's investment into DP Me...
Foresight Group (“Foresight”), a FTSE 250 listed private equity and infrastructure investment manager, has completed a €5.3 million investment into DP Medica...